Clinical Trials Browser

Phase 2 × Urinary Bladder Neoplasms × Rogaratinib × Clear all

NCT04040725 2019-12-17

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Phase 2 Withdrawn

Urinary Bladder Neoplasms